Frank Jacobs
Overview
Explore the profile of Frank Jacobs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1060
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kwon M, Thuring J, Querolle O, Dai X, Verhulst T, Pande V, et al.
Blood
. 2024 Jun;
144(11):1206-1220.
PMID: 38905635
The interaction between menin and histone-lysine N-methyltransferase 2A (KMT2A) is a critical dependency for KMT2A- or nucleophosmin 1 (NPM1)-altered leukemias and an emerging opportunity for therapeutic development. JNJ-75276617 (bleximenib) is...
2.
Harwood M, Zettl K, Weinheimer M, Pilla-Reddy V, Shen H, Jacobs F, et al.
Mol Pharm
. 2023 Jun;
20(7):3505-3518.
PMID: 37283406
Madin-Darby canine kidney (MDCK) cells are widely used to study epithelial cell functionality. Their low endogenous drug transporter protein levels make them an amenable system to investigate transepithelial permeation and...
3.
Smits F, Jacobs F, Knoppers A
Front Psychol
. 2022 Jun;
13:829352.
PMID: 35712134
Abusive practices in elite women's artistic gymnastics (WAG) have been the focus of discussions about how to eliminate or reduce them. Both coaches and parents have been named as key...
4.
Willemin M, van der Made T, Pijpers I, Dillen L, Kunze A, Jonkers S, et al.
Clin Pharmacokinet
. 2022 Feb;
61(3):463.
PMID: 35175504
No abstract available.
5.
de Zwart L, Snoeys J, Jacobs F, Li L, Poggesi I, Verboven P, et al.
CPT Pharmacometrics Syst Pharmacol
. 2021 Jul;
10(9):1107-1118.
PMID: 34273250
Erdafitinib is a potent oral pan-fibroblast growth factor receptor inhibitor being developed as oncology drug for patients with alterations in the fibroblast growth factor receptor pathway. Erdafitinib binds preferentially to...
6.
Willemin M, van der Made T, Pijpers I, Dillen L, Kunze A, Jonkers S, et al.
Clin Pharmacokinet
. 2021 Apr;
60(9):1187-1199.
PMID: 33840062
Background: Endogenous biomarkers are promising tools to assess transporter-mediated drug-drug interactions early in humans. Methods: We evaluated on a common and validated in vitro system the selectivity of 4-pyridoxic acid...
7.
Ahmad A, Ogungbenro K, Kunze A, Jacobs F, Snoeys J, Rostami-Hodjegan A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2021 Mar;
10(5):467-477.
PMID: 33704919
Renal clearance of many drugs is mediated by renal organic anion transporters OAT1/3 and inhibition of these transporters may lead to drug-drug interactions (DDIs). Pyridoxic acid (PDA) and homovanillic acid...
8.
Boon R, Kumar M, Tricot T, Elia I, Ordovas L, Jacobs F, et al.
Nat Commun
. 2020 Mar;
11(1):1393.
PMID: 32170132
Predicting drug-induced liver injury in a preclinical setting remains challenging, as cultured primary human hepatocytes (PHHs), pluripotent stem cell-derived hepatocyte-like cells (HLCs), and hepatoma cells exhibit poor drug biotransformation capacity....
9.
de Vries R, Jacobs F, Mannens G, Snoeys J, Cuyckens F, Chien C, et al.
Drug Metab Dispos
. 2019 Feb;
47(5):453-464.
PMID: 30787101
In this phase 1 study, the absolute bioavailability and absorption, metabolism, and excretion (AME) of apalutamide, a competitive inhibitor of the androgen receptor, were evaluated in 12 healthy men. Subjects...
10.
Bell C, Dankers A, Lauschke V, Sison-Young R, Jenkins R, Rowe C, et al.
Toxicol Sci
. 2018 Jan;
162(2):655-666.
PMID: 29329425
Primary human hepatocytes (PHHs) are commonly used for in vitro studies of drug-induced liver injury. However, when cultured as 2D monolayers, PHH lose crucial hepatic functions within hours. This dedifferentiation...